Pharmacokinetics

Yacoub Irshaid MD, PhD, ABCP
Department of Pharmacology

Pharmacokinetics

- **Is what the body does to the drug.**
- **Deals with absorption, distribution, biotransformation and excretion of drugs:**

1. **Absorption: Is the movement of drug molecules from the site of administration into the circulation.**

Pharmacokinetics

2. **Distribution: Is the movement of drug molecules from the circulation to tissues and between different parts of the body.**
3. **Biotransformation: Is conversion of the drug from one chemical structure into another by the action of metabolic enzymes (metabolism).**
4. **Excretion: Is the movement of drug molecules out of the body through urine and/or bile.**

Primary Principles

- **The goal of therapeutics is to achieve a desired beneficial effect with the minimal adverse effects possible.**
- **The clinician must determine the dose that most closely achieves this goal.**
- **A fundamental hypothesis of pharmacology is that a relationship exists between a beneficial or toxic effect of a drug and the concentration of the drug at the site of action (or in the blood).**

Mechanisms of Permeation of Drug Molecules

- **The drug has to reach the site of action in order to be effective.**
- **The movement of the drug between compartments in the body requires passage through membranes.**

1. **Lipid diffusion (Passive diffusion):**

- **The most important mechanism.**
- **The drug dissolves in the membrane.**

Mechanisms of Permeation of Drug Molecules

- **The more lipid soluble is a drug, the more will be its passage across membranes and vice versa.**
- **The drug has to be sufficiently water soluble to reach the membrane.**
- **The drug follows the concentration gradient.**



Fick's Law of Diffusion

- **It governs the passive flux of molecules across membranes.**
- **Flux (molecules/unit time) =**
  C_1-C_2 x [(Area x Permeability coefficient)/ Thickness]

  C_1 is the higher concentration and C_2 is the lower concentration; area is the area across which diffusion occurs; permeability coefficient is a measure of the mobility of drug molecules in the medium of diffusion path; and thickness is the thickness or length of diffusion path.

Mechanisms of Permeation of Drug Molecules

- **Most drugs are either weak acids or weak basis.**
- **Therefore, the pKa of the drug and the pH of the medium will affect lipid solubility of the drug and its passage across membranes.**
- **Ionized drug molecules are polar and water soluble, whereas unionized drug molecules are nonpolar and lipid soluble.**

Mechanisms of Permeation of Drug Molecules

Ionization of weak acids and basis:

- **A weak acid is a neutral molecule that can reversibly dissociate into an anion (negatively charged molecule) and a proton (a hydrogen ion).**

R-COOH ⟷ **$R\text{-}COO^- + H^+$**

Lipid soluble — **water soluble**

Mechanisms of Permeation of Drug Molecules

- **A weak base is a neutral molecule that can form a cation (positively charged molecule) by combining with a proton.**



Mechanisms of Permeation of Drug Molecules

- These reactions move to the left in an acid environment and to the right in an alkaline environment.

Henderson-Hasselbalch Equation:

Log [protonated/unprotonated] = pKa – pH

- This equation applies to both acidic and basic drugs.

Mechanisms of Permeation of Drug Molecules

Examples:

1. **Pyrimethamine as a weak base drug with a pKa of 7.0.**

   What is the proportion of ionized and unionized drug in blood (pH = 7.4) and urine (pH = 6)?

Mechanisms of Permeation of Drug Molecules

- **Blood:**

  Log (prot/unprot) = pKa – pH =7-7.4 = - 0.4

  Prot/unprot = $10^{-0.4}$ = 0.4:1 = 0.4/1.4

- **Urine:**

  Log (prot/unprot) = pKa – pH =7-6 =1

  Prot/unprot = 10^{1} = 10:1 = 10/11.

Mechanisms of Permeation of Drug Molecules

2. **Phenobarbital is a weak acid with a pKa of 7.4.**

   What is the proportion of ionized and unionized drug in blood (pH = 7.4) and urine (pH = 6)?

Mechanisms of Permeation of Drug Molecules

- **Blood:**

  Log (prot/unprot) = pKa – pH

  = 7.4-7.4 = 0

  Prot/Unprot = 10^0 = 1:1 =1/2

- **Urine:**

  Log (prot/unprot) = pKa – pH

  = 7.4 – 6 = 1.4

  Prot/Unprot = $10^{1.4}$ =25:1 = 25/26

Mechanisms of Permeation of Drug Molecules

- **The lower the pH relative to the pKa, the greater will be the fraction of the drug in the protonated form.**
- **Acids in an acid environment are unionized (non-polar).**
- **Bases in an alkaline environment are unionized (non-polar).**

Mechanisms of Permeation of Drug Molecules

- **The protonated weak acid is neutral and more lipid soluble.**
- **The unprotonated weak base is neutral and more lipid soluble.**
- **In an acid environment, the acidic drug is neutral while the basic drug is ionized.**
- **In an alkaline environment, the acidic drug is ionized while the basic drug is neutral.**

Mechanisms of Permeation of Drug Molecules

Application:

Manipulation of drug excretion by the kidney:

- **If the drug is filtered in urine in unionized form, it will be reabsorbed by renal tubules.**
- **If we want to accelerate excretion of drug from the body (in case of overdose), it is important to ionize the drug within the renal tubules to reduce reabsorption.**

Mechanisms of Permeation of Drug Molecules

- **This can be accomplished by changing urine pH.**
- **Weak acids are excreted faster in alkaline urine. Urine can be alkalinized by sodium bicarbonate ($NaHCO_3$) given orally or intravenously.**
- **Weak basis are excreted faster in acidic urine. Urine can be acidified by ascorbic acid (vitamin C) or ammonium chloride (NH_4Cl).**

Mechanisms of Permeation of Drug Molecules

2. Aqueous diffusion:

- Through aqueous pores in membranes.
- Also driven by the concentration gradient.
- Drugs bound to plasma proteins do not permeate aqueous pores.
- If the drug is charged, its flux is influenced by electrical fields (membrane potentials).

Mechanisms of Permeation of Drug Molecules

3. **Special carriers (carrier-mediated transport):**

- **Exist for substances that are important for cell function and are too large or too insoluble in lipids to diffuse passively though membranes (peptides, amino acids, glucose, etc).**
- **They bring about drug movement by active transport or facilitated diffusion.**

Mechanisms of Permeation of Drug Molecules

- **They are selective, saturable and inhibitable.**
- **Many cells contain less selective membrane carriers that are specialized in expelling foreign molecules including drugs:**

A. ATP-binding cassette (ABC) family:

- **It includes P-glycoprotein or the multidrug-resistance type 1 (MDR1) transporter found in the brain, intestine, testes, neoplastic cells, and other tissues.**

Mechanisms of Permeation of Drug Molecules

B. The multidrug-resistance associated protein (MRP) transporters (also from the ABC family):

- **They play a role in excretion of drugs and their metabolites into urine and bile.**
- **They mediate the resistance of some tumors to chemotherapeutic agents.**

Mechanisms of Permeation of Drug Molecules

C. The solute carrier families (SLC):

- **They do not bind ATP but use ion gradients for transport energy.**
- **They are important in the transport or the uptake of neurotransmitters across nerve ending membranes.**

Mechanisms of Permeation of Drug Molecules

4. **Endocytosis and exocytosis:**

- **Endocytosis is responsible for transport of vitamin B_{12} complexed with the intrinsic factor across the wall of the gut into the blood, and iron associated with transferrin into RBCs.**
- **Exocytosis is responsible for secretion of many substances from cells such as neurotransmitters and some hormones.**

Mechanisms of Permeation of Drug Molecules

- ***These principles of permeation of drug molecules apply to drug absorption, distribution and elimination.***
- ***These processes determine how rapidly and for how long the drug will appear in the target organ, the site of action, and organs of elimination.***

Barriers Against Drug Permeation & Transport

1. Tight junctions between endothelial cells and absence of pores.
2. The presence of thick basement membrane at which endothelial cells lie.
3. The presence of connective tissue cells around endothelial cells (such as astrocytes in the brain).
4. The presence of drug export pumps.
5. The presence of intracellular and extracellular enzymes that metabolize drugs.

First-Pass Effect

- **Drugs absorbed from the GIT must pass through the gut wall and portal vein to the liver before reaching the systemic circulation.**
- **The drug may be metabolized in the gut wall, portal vein, and the liver prior to entry to the systemic circulation.**
- **Or, it may get excreted by the liver through bile.**

First-Pass Effect

- **This will lead to incomplete delivery of the dose given to the systemic circulation.**
- **This process is called "first-pass effect" or "first-pass metabolism" or "pre-systemic elimination".**


Gut Lumen
Gut Wall
Portal Vein
Liver
To Site of Measure-ment
Syst. Circ.
(Hepatic vein)
IVC
Metabolism
Metabolism
To Feces
Biliary Excretion

First-Pass Effect

- **Therapeutic blood concentration may still be reached by using larger dose.**
- **Therefore, the oral dose is usually higher than intravenous dose for such drugs.**
- **Also the concentration of drug metabolites after oral administration will be higher than after intravenous administration (why?).**

First-Pass Effect

- **If the patient is having liver cirrhosis and there is shunting of blood by-passing the portal circulation, giving a larger dose orally will lead to substantial increases in concentration of the drug and drug toxicity.**

Bioavailability

- **It is the fraction of the unchanged active drug reaching the systemic circulation, following drug administration; irrespective of the route.**
- **It is equal to “1” or 100% following intravenous drug administration.**
- **After oral administration, bioavailability may be less than 1, because of:**

Bioavailability

1. First-pass effect.
2. Incomplete absorption.
3. Incomplete disintegration and dissolution.
4. Destruction of drug within GIT lumen by gastric acid, bacteria, ..etc.
5. Faulty manufacturing of the dosage form.
6. Enterhepatic cycling.

Dosage form

↓

Disintegration

↓

Dissolution

↓ ***absorption***

Drug in the systemic circulation

Bioavailability

- **The area under the blood concentration *versus* time curve (AUC) is a common measure of the extent of bioavailability.**
- **Causes of reduction of the extent of absorption:**

Bioavailability

1. **The drug may be too hydrophilic (atenolol), or too lipophilic (acyclovir), to be absorbed easily.**
- **Too hydrophilic drugs can NOT cross lipid membranes easily.**
- **Too lipophilic drugs are NOT water soluble enough to reach the membrane (to cross the water layer adjacent to the cell).**

Bioavailability

2. **Drugs may NOT be absorbed because of the presence of a reverse transporter (P-glycoprotein) that pumps the drug out of the gut wall cells back into the gut lumen.**

Bioavailability

- **Inhibition of the reverse transporter by the use of some drugs and grapefruit juice, may be associated with substantial increase in drug absorption and thus bioavailability.**
- **Grapefruit juice also inhibits presystemic elimination of some drugs, and thus, increases their bioavailability.**


MTC
Peak concentration
MEC
Plasma level
AUC
Peak
time
Time



Source: Shargel L, Wu-Pong S, Yu ABC: *Applied Biopharmaceutics & Pharmacokinetics, 6th Edition*: www.accesspharmacy.com

Effect of First-Pass Effect on bioavailability

- **The effect of first-pass hepatic elimination on bioavailability is expressed as the extraction ratio (ER):**
- **Bioavailability (F) = 1-ER.**
- **If absorption is not complete, bioavailability (F) can be predicted from the extent of absorption (f) and ER.**

$$F = (f) \,.\, (1 - ER)$$

Effect of First-Pass Effect on bioavailability

- **A drug like morphine is completely absorbed but its ER is 0.67, so its bioavailability is 33%.**
- **Drugs with high extraction ratio exhibit interindividual differences in bioavailability and drug concentration, because of differences among individuals in hepatic blood flow and hepatic drug metabolism.**

Bioequivalence

- **This term is used to compare the rate and extent of absorption of different formulations (or dosage forms) of the same active drug.**
- **The extent of absorption is measured by AUC, and the rate is assessed by C_{max} (peak concentration) and T_{max} (time to peak concentration).**


MTC
Peak concentration
MEC
Plasma level
AUC
Peak
time
Time



FIGURE 3-4 Blood concentration-time curves, illustrating how changes in the rate of absorption and extent of bioavailability can influence both the duration of action and the effectiveness of the same total dose of a drug administered in three different formulations. The dashed line indicates the target concentration (TC) of the drug in the blood.

A



Enterohepatic Cycling of Drugs

- **After oral administration and absorption, a drug can be excreted in bile before reaching the systemic circulation, go back to gut lumen, and then reabsorbed again.**
- **This is called enterohepatic cycling of the drug.**
- **It reduces drug bioavailability and prolongs its half-life of elimination.**

Enterohepatic Circulation

- Is recirculation of compounds between liver and intestine
- Many compounds are released in bile, reabsorbed in SI, and returned to liver to be recycled
- Liver excretes drug metabolites into bile to pass out in feces



Enterohepatic Cycling of Drugs

Application:

- **This phenomenon can be taken advantage of in cases of drug overdose, to enhance drug elimination from the body.**
- **Activated charcoal can adsorb may drugs and chemicals (except ionized ones, and petroleum distillates) into its surface.**

Enterohepatic Cycling of Drugs

- **If we give activated charcoal orally in cases of drug overdose, and the drug undergoes enterohepatic cycling, then the portion of the drug that is excreted into the gut through bile can be trapped and prevented from reabsorption back into the systemic circulation.**
- **This will accelerate drug elimination from the body and reduces its half-life of elimination.**

Volume of Distribution (V_D)

- It is the size of body fluid that would be required if the drug molecules were to be homogeneously distributed through all parts of the body.
- It reflects the apparent space available for the drug in the tissues of distribution.
- It does NOT represent a real volume.

Volume of Distribution (V_D)

- **In a normal 70 Kg man, the volume of:**

Plasma	**= 2.8 L**
Blood	**= 5.6 L**
ECF	**= 14 L**
TBW	**= 42 L**
Fat	**= 14 - 25 L**

- **But the volume of distribution for:**

Aspirin	**= 11 L**
Ampicillin	**= 20 L**
Phenobarbital	**= 40 L**
Digoxin	**= 640 L**
Imipramine	**= 1600 L**
Chloroquine	**= 13000 L**

Volume of Distribution (V_D)

- **The apparent volume of distribution will be small if the drug is restricted to plasma:**

1. **due to binding to plasma proteins**
2. **when it is highly ionized at plasma pH.**

- **The apparent volume of distribution will be large when the drug distributes into tissues.**
- **It relates the amount of the drug in the body (Ab), with its plasma concentration (Cp), such that: $V_D = Ab/Cp$**

Drug Binding in Plasma

- **Albumin is the most important drug- binding protein.**
- **α_1- Acid-glycoprotein is also important for binding certain basic drugs.**
- **Binding to plasma proteins is mostly reversible.**

Drug + Protein ⟷ **Drug-Protein complex**

D + P ⟷ **DP**

Drug Binding in Plasma

- **The free unbound drug fraction (D) is responsible for the pharmacological action and is also available for elimination.**
- **The bound drug fraction (DP) is not so available, and it represents a reservoir for the drug.**
- **One clinical importance of plasma protein binding of drugs is to help interpretation of measured plasma drug concentration of such drugs.**

Drug Binding in Plasma

- When plasma protein concentrations are lower than normal, then the total drug concentration will be lower than expected, but the free concentration may not be affected (why?).
- Plasma protein binding is also a site for drug-drug interactions.
- If a drug is displaced from plasma proteins it would increase the unbound drug concentration and increase the drug effect and, perhaps, produce toxicity.

Drug Binding in Plasma

- **Drug displaced from plasma protein will of course distribute throughout the volume of distribution, and its rate of elimination will also increase, thus, its plasma concentration will NOT increase dramatically.**

Drug Clearance (CL)

- It is the volume of blood or plasma that is completely cleared of drug per unit time.
- It is a measure of the ability of the body to eliminate (and distribute) the drug.
- Clearance of a drug is the factor that predicts the rate of elimination in relation to the drug concentration:

  CL = rate of elimination/Cp

Drug Clearance (CL)

- **Assume that the rate of elimination of a drug is 10 mg/hour, and the plasma concentration is 1 mg/L. What is drug clearance?**
- **CL = [10 mg/hour] / [1 mg/L]**
  = 10 L/hour

Drug Clearance (CL)

- **There may be more than one method of elimination, and thus the rate of elimination will be the sum of all these methods.**

- **Renal clearance (CL_R) = Cu.V/Cp ,**

  where Cu is concentration of drug in urine, V is urine flow rate, and Cp is the plasma concentration of the drug.

Drug Clearance (CL)

- **Hepatic clearance (CL_H) =**
  [(blood flow. C_i)- (blood flow. C_o)]/ C_i
  CL_H = blood flow (C_i- C_o)/ C_i
  CL_H = Q.ER

  C_i is drug concentration in blood going to the liver, C_o is drug concentration in blood leaving the liver, Q is blood flow, ER is the extraction ratio of the drug.

First-Order Drug Elimination

- It occurs when the rate of drug elimination is directly proportional to the amount of drug in the body.
- Occurs with many drugs at therapeutic concentrations.
- A constant fraction of the drug is eliminated per unit time.
- The elimination rate constant is designated as k, and its units are reciprocal time (1/time) meaning fraction per unit time.



Source: Shargel L, Wu-Pong S, Yu ABC: *Applied Biopharmaceutics & Pharmacokinetics, 6th Edition*: www.accesspharmacy.com

Zero-Order Drug Elimination

- Also called Saturable elimination.
- Occurs with few drugs (aspirin, phenytoin, ethanol, ..).
- Elimination rate is NOT proportional to the amount of drug in the body, but a constant amount is removed per unit time, because of saturation of the elimination process.



Source: Shargel L, Wu-Pong S, Yu ABC: *Applied Biopharmaceutics & Pharmacokinetics, 6th Edition*: www.accesspharmacy.com

Zero-Order Drug Elimination

- **Rate of elimination = V_{max}. C / K_m + C**

Where V_{max} is the maximal elimination capacity, and K_m is the drug concentration at which rate of elimination is 50% of V_{max}.



Source: Shargel L, Wu-Pong S, Yu ABC: *Applied Biopharmaceutics & Pharmacokinetics, 6th Edition*: www.accesspharmacy.com

Curve C represent first-order kinetics

Flow-Dependent Drug Elimination

- Some drugs are cleared very rapidly by the organ of elimination (liver), so that at clinical concentrations of the drug, most of the drug perfusing the liver is eliminated on first pass through it.
- Rate of elimination is determined by the rate of hepatic blood flow.
- Drugs that have this property are called "high extration ratio" drugs.
- Include morphine, lidocaine, propranolol, verapamil, and others.

Half-Life (t½) of Elimination

- It is the time required for the amount of drug in the body or the plasma concentration of the drug (assuming first-order elimination) to drop by 50%.
- In this case it is constant, and not related to dose.
- After ~ 4 half-lives, most of the drug will be eliminated from the body.
- It is related to first-order elimination rate constant such that:

$$k \times t_{1/2} = 0.693$$

Half-lives	% of drug removed
1	50
2	75
3	87.5
4	93.75


100
50
10
5
1
Drug concentration (µg/mL)
$t_{1/2}$
$t_{1/2}$
0
4
8
12
14
20
24
Time (hours)

Half-Life (t½) of Elimination

- **The half-life is related to volume of distribution and clearance for drugs that follow first-order kinetics by the following equation:**

$$CL = k.Vd$$

$$t_{½} = 0.693\ Vd/CL$$

Half-Life (t½) of Elimination

- **It is related to dose and plasma concentration for drugs undergoing zero-order kinetics, and is NOT constant.**
- **The higher the concentration, the longer the half-life of elimination and vice versa.**

Steady-State

- Steady-state is a condition achieved following repeated drug administration as occurs in clinical practice.
- It occurs when the rate of drug administration (dosing rate) is equal to the rate of drug elimination.
- At steady-state, a constant peak, trough, and average drug concentrations are achieved.


Steady State
· Attained after approximately four half-times
· Time to steady state independent of dosage
Steady State Concentrations
CONCENTRATION
0
1
2
0
1
2
3
4
5
6
TIME (multiples of elimination half-time)

Steady-State

- **Steady-state is achieved after approximately 4 half-lives of repeated drug administration. 50% of SS is achieved after one half-life of administration.**
- **Our aim during drug therapy is to attain a steady-state drug concentration (Css) within the therapeutic range, but NOT subtherapeutic or toxic.**



Fig. 11.9 Comparison of non-saturating and saturating kinetics for drugs given orally every 12 h. (A) The curves showing an imaginary drug, similar to the antiepileptic drug phenytoin at the lowest dose, but with linear kinetics. The steady-state plasma concentration is reached within a few days, and is directly proportional to dose. (B) Curves for saturating kinetics calculated from the known pharmacokinetic parameters of phenytoin (see Ch. 45). Note that no steady state is reached with higher doses of phenytoin, and that a small increment in dose results after a time in a disproportionately large effect on plasma concentration. (Curves were calculated with the Sympak pharmacokinetic modelling program written by Dr J.G. Blackman, University of Otago.)

Loading Dose (LD)

- **When the half-life is too long, steady-state will take a long time to be achieved.**
- **Therefore, we may need to give a loading dose to achieve drug concentration within the therapeutic range sooner (target concentration).**

$$LD = V_D \cdot Css_{desired}$$

Maintenance Dose (MD)

- **To attain and maintain a desired Css of a drug, we need to adjust the dose so that, the rate of drug administration is equal to the rate of drug elimination.**
- **Elimination is a function of clearnce.**

$$MD = CL.\ Css_{desired}$$

$Css_{desired}$ is also called the target concentration.